CENTRAL TRUST Co Trims Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CENTRAL TRUST Co decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) by 9.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,030 shares of the specialty pharmaceutical company’s stock after selling 1,521 shares during the quarter. CENTRAL TRUST Co’s holdings in Jazz Pharmaceuticals were worth $2,004,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. TD Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 2.5% during the 3rd quarter. TD Asset Management Inc. now owns 4,949 shares of the specialty pharmaceutical company’s stock worth $655,000 after buying an additional 122 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Jazz Pharmaceuticals by 7.7% during the third quarter. Envestnet Asset Management Inc. now owns 49,688 shares of the specialty pharmaceutical company’s stock valued at $6,623,000 after purchasing an additional 3,566 shares in the last quarter. Prudential Financial Inc. boosted its position in Jazz Pharmaceuticals by 3,731.5% during the third quarter. Prudential Financial Inc. now owns 311,383 shares of the specialty pharmaceutical company’s stock valued at $41,503,000 after purchasing an additional 303,256 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Jazz Pharmaceuticals by 15.0% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 6,431 shares of the specialty pharmaceutical company’s stock valued at $857,000 after purchasing an additional 841 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in Jazz Pharmaceuticals by 82,332.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 23,081 shares of the specialty pharmaceutical company’s stock valued at $3,075,000 after purchasing an additional 23,053 shares in the last quarter. Institutional investors own 89.79% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Kenneth W. O’keefe sold 2,690 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $138.39, for a total value of $372,269.10. Following the completion of the sale, the director now owns 22,889 shares of the company’s stock, valued at $3,167,608.71. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, SVP Samantha Pearce sold 531 shares of the company’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $159.59, for a total value of $84,742.29. Following the completion of the sale, the senior vice president now owns 11,309 shares of the company’s stock, valued at $1,804,803.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kenneth W. O’keefe sold 2,690 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $138.39, for a total transaction of $372,269.10. Following the transaction, the director now directly owns 22,889 shares in the company, valued at $3,167,608.71. The disclosure for this sale can be found here. Insiders have sold a total of 15,723 shares of company stock worth $2,342,138 in the last ninety days. Insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JAZZ. StockNews.com downgraded Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 7th. HC Wainwright restated a “buy” rating and issued a $204.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, March 6th. Needham & Company LLC reduced their price objective on Jazz Pharmaceuticals from $210.00 to $205.00 and set a “buy” rating for the company in a research note on Thursday, March 2nd. Finally, The Goldman Sachs Group raised their price objective on Jazz Pharmaceuticals from $190.00 to $212.00 and gave the stock a “buy” rating in a research note on Friday, March 3rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $204.27.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $134.89 on Thursday. The company has a market cap of $8.54 billion, a P/E ratio of -38.00, a P/E/G ratio of 0.76 and a beta of 0.73. Jazz Pharmaceuticals plc has a twelve month low of $125.36 and a twelve month high of $169.98. The company’s 50-day moving average price is $149.41 and its 200-day moving average price is $147.58. The company has a current ratio of 2.79, a quick ratio of 2.03 and a debt-to-equity ratio of 1.85.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.